Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
443.92
+12.06 (+2.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 11, 2026
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
The Best Stocks to Invest $50,000 in Right Now
↗
January 11, 2026
These stocks should be good bets in the new year.
Via
The Motley Fool
Topics
Artificial Intelligence
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge
January 09, 2026
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...
Via
MarketMinute
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Compelling Value Stock Candidate
↗
January 01, 2026
Via
Chartmill
Prediction: 2 Healthcare Stocks That Will Be Worth More Than Pfizer by the End of 2026
↗
January 09, 2026
It could be another tough year for the once-soaring drugmaker.
Via
The Motley Fool
Topics
Intellectual Property
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
January 07, 2026
Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...
Via
PredictStreet
Topics
Economy
Initial Public Offering
Intellectual Property
Stocks making big moves yesterday: Herbalife, Vertex Pharmaceuticals, Micron, Amkor, and Palantir Technologies
January 07, 2026
Check out the companies making headlines yesterday:
Via
StockStory
Topics
Artificial Intelligence
Vertex Pharmaceuticals (VRTX) Stock Trades Up, Here Is Why
January 06, 2026
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 3.8% in the afternoon session after Wolfe Research upgraded the stock from "Peer Perform" to "Outperform" and issued a $548 price...
Via
StockStory
My 10 Top Stocks to Buy to Start the New Year Off Right
↗
January 05, 2026
Investing in a few of these players could increase the diversification of your portfolio.
Via
The Motley Fool
Topics
Artificial Intelligence
BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations
January 02, 2026
As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
The Best Stocks to Invest $1,000 in to Start the New Year Off Right
↗
January 01, 2026
These three stocks could make 2026 a happy new year for investors.
Via
The Motley Fool
Topics
Artificial Intelligence
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
December 31, 2025
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Stay informed with the top movers within the S&P500 index on Tuesday.
↗
December 30, 2025
Via
Chartmill
Discover which S&P500 stocks are making waves on Tuesday.
↗
December 30, 2025
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.
Via
Chartmill
2 Growth Stocks to Buy For 2026 and Beyond
↗
December 30, 2025
Neither had a great year in 2025, but the future is looking bright.
Via
The Motley Fool
Topics
Economy
2 Nasdaq 100 Stocks Worth Investigating and 1 We Turn Down
December 28, 2025
The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or...
Via
StockStory
Topics
Electric Vehicles
World Trade
3 Supercharged Growth Stocks to Buy and Hold Into the 2030s
↗
December 28, 2025
Growth stocks fall in and out of favor with investors, but quality businesses are always worth buying.
Via
The Motley Fool
Topics
Artificial Intelligence
Forget Moderna Stock, This is a Much Better Buy
↗
December 27, 2025
This stock is a great choice for cautious and aggressive investors.
Via
The Motley Fool
Topics
Intellectual Property
The $1.7 Billion Pivot: Agios Pharmaceuticals (AGIO) and the New Frontier of Oral Thalassemia Therapy
December 24, 2025
On December 23, 2025, the biotechnology landscape shifted for thousands of patients living with chronic anemia. The U.S. Food and Drug Administration (FDA) granted approval to AQVESME (mitapivat),...
Via
PredictStreet
Topics
Economy
Is CRISPR Therapeutics Stock Yesterday's News?
↗
December 24, 2025
The biotech sells blood disorders treatment, Casgevy.
Via
The Motley Fool
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
December 22, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
December 22, 2025
As of December 22, 2025, Moderna, Inc. (NASDAQ: MRNA) stands at a critical juncture in its corporate evolution. Once the poster child for the biotechnology industry’s rapid response to the global...
Via
PredictStreet
Topics
Earnings
Initial Public Offering
Intellectual Property
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A GARP Case Study in Affordable Growth
↗
December 22, 2025
Vertex Pharmaceuticals (VRTX) exemplifies GARP investing, offering strong earnings growth, top profitability, and a debt-free balance sheet at a reasonable market valuation.
Via
Chartmill
2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky
December 21, 2025
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via
StockStory
Is CRISPR Therapeutics a Buy, Sell, or Hold in 2026?
↗
December 19, 2025
Next year could be crucial for the company as sales for its only approved treatment could take off.
Via
The Motley Fool
2 Reasons to Watch VRTX and 1 to Stay Cautious
December 17, 2025
Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that...
Via
StockStory
Topics
Stocks
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
December 16, 2025
Issued on behalf of Avant Technologies Inc.
From
USA News Group
Via
GlobeNewswire
12 Days of Investing: My Top 12 Stocks to Buy Before 2026
↗
December 15, 2025
The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.
Via
The Motley Fool
Topics
Artificial Intelligence
Vertex Pharmaceuticals (NASDAQ:VRTX) Combines Strong Growth with Technical Breakout Potential
↗
December 15, 2025
Vertex Pharmaceuticals (VRTX) shows strong growth fundamentals and a positive technical breakout setup, combining high earnings forecasts with a promising stock chart pattern.
Via
Chartmill
2 Healthcare Stocks to Buy Ahead of the New Year
↗
December 12, 2025
These companies could innovate their way to success.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
72
73
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.